GlassScriptPhysician profile
Ian J Molk
NPI 1073546636
$3,737.59
in general payments reported to CMS, 2019-2025
23 companies · $43.74 in 2025
The $43.74 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $959 · 2020: $886 · 2021: $912 · 2022: $236 · 2023: $519 · 2024: $182 · 2025: $43.74.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $745.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $745.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $709.84 | 2019-2023 | Aveir, Assurity |
| Astellas Pharma US INC | $367.09 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $320.61 | 2019-2022 | |
| Boston Scientific Corporation | $298.70 | 2019-2023 | Watchman |
| Astrazeneca Pharmaceuticals LP | $260.59 | 2019-2023 | Farxiga |
| Amgen INC. | $242.87 | 2019-2023 | Repatha |
| Amarin Pharma, INC. | $227.73 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $206.51 | 2019-2023 | Jardiance |
| Novartis Pharmaceuticals Corporation | $189.76 | 2019-2025 | |
| Arbor Pharmaceuticals, INC. | $156.45 | 2019-2021 | |
| Impulse Dynamics (USA) INC. | $155.28 | 2021 | |
| Pfizer INC. | $134.62 | 2019-2024 | |
| Cvrx, INC. | $113.70 | 2024 | Barostim Neo System |
| Sanofi-Aventis U.S. LLC | $64.64 | 2019-2021 | |
| Biotronik INC. | $64.23 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $45.07 | 2021-2022 | |
| Novo Nordisk INC | $43.22 | 2024-2025 | Wegovy |
| Irhythm Technologies, INC. | $28.52 | 2022 | |
| Amryt Pharma Holdings LTD | $28.29 | 2020-2021 | |
| Heartflow, INC. | $24.66 | 2024 | |
| Kowa Pharmaceuticals America, INC. | $22.36 | 2020-2021 | |
| Bardy Diagnostics, INC. | $20.00 | 2020 | |
| Kiniksa Pharmaceuticals, LTD. | $12.85 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ian Molk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.